



22 May 2023
EMA/CVMP/206714/2023
Committee for Veterinary Medicinal Products

MRL summary opinion¹

Ketoprofen

Poultry

On 16 May 2023, the Committee for Veterinary Medicinal Products adopted an opinion² recommending the extension of maximum residue limits for ketoprofen to chicken in accordance with the table below. Furthermore, with reference to Article 5 of Regulation (EC) No 470/2009 and in line with the criteria laid down in Commission Regulation (EU) 2017/880, the Committee agreed to extrapolate the conclusions to poultry. Therefore, the amendment of the entry for ketoprofen in Table 1 (allowed substances) of the Annex to Commission Regulation (EU) No 37/2010 of 22 December 2009, is recommended as follows:

Pharmacologically active substance	Marker residue	Animal species	MRLs	Target tissues	Other provisions	Therapeutic classification
Ketoprofen	Ketoprofen	Bovine, porcine, <i>Equidae</i>	No MRL required	NOT APPLICABLE	NO ENTRY	NO ENTRY
		Poultry	10 µg/kg 30 µg/kg 10 µg/kg 10 µg/kg	Muscle Skin and fat in natural proportion Liver Kidney	Not for use in animals from which eggs are produced for human consumption	NO ENTRY

¹ Summaries of opinion are published without prejudice to the Commission Decision.

² Applicants may request re-examination of any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to request such re-examination within 15 days of receipt of the opinion

